Testagen

What it is. Testagen is Lys-Glu-Asp-Gly, one of the organ-designated tetrapeptides in the Khavinson programme [1][3]. The name and the marketing both point at reproductive function.

What its literature actually contains. One biological study. In the 2011 paper that underpins the whole family's mechanistic claim, fluorescein-labelled testagen - alongside epithalon and pinealon - was shown to enter the cytoplasm, nucleus and nucleolus of HeLa cells. In vitro it quenched the fluorescence of labelled deoxyribooligonucleotides with sequence-dependent constants, preferring CAG-containing sequences and discriminating their cytosine methylation status [1].

That is a real result and it is the best mechanistic evidence this family has. It was obtained in a cervical cancer cell line and it concerns DNA binding. It has no connection to reproductive tissue.

The other paper. In 2025, testagen was studied as a corrosion inhibitor for copper surfaces in saline environments, with experimental and computational characterisation of its adsorption properties [2]. Short charged peptides adsorb to metal surfaces, and this is a perfectly reasonable materials-science application. It is included here because it is, remarkably, half of the peptide's indexed literature.

What is absent. Any measurement of testosterone. Any study of spermatogenesis or sperm parameters. Any fertility endpoint. Any animal model of reproductive function. Any human study. Any pharmacokinetics.

The organ designation derives from the programme's design principle - a peptide built from the amino acid composition of an organ extract is assigned to that organ [3]. For testagen, that assignment has never been tested.

The demonstrated mechanism is DNA binding. Labelled testagen reaches the nucleus of cultured cells and binds oligonucleotides with a preference for CAG motifs [1]. Since CNG sites are targets for cytosine methylation, the source paper proposes an epigenetic route by which such binding could control gene activity - as a hypothesis, not a finding.

Nothing connects that to reproductive biology. There is no proposed receptor, no androgen-pathway interaction, no tissue distribution study, and no measurement of any reproductive gene or hormone.

It is worth noting that the sequence preference demonstrated in that paper is itself an argument against assuming testagen behaves like its siblings: bronchogen preferred CTG where testagen, epithalon and pinealon preferred CAG [1]. If sequence determines target, each peptide needs its own evidence.

The free tetrapeptide Lys-Glu-Asp-Gly, supplied lyophilised. No route, dose or formulation for use in an organism has been published.

There is no safety data of any kind: no toxicology, no animal study, no human exposure report.

The absence of reported harm reflects the absence of investigation.

Two points worth stating for a compound marketed for hormonal support. Nothing published establishes that it affects any hormone, so there is no basis for either expecting or excluding endocrine effects. And a peptide demonstrated to enter cell nuclei and bind DNA [1] is one for which genotoxicity testing would be routine in any development programme; none has been published.

No interaction data exist. Testagen was examined alongside epithalon, pinealon and bronchogen in the DNA-binding study as a comparison rather than a combination [1].